Ticker Symbol: ATXI
Avenue Therapeutics Inc
$1.38 - 21-10-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001644963
Company Profile
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 2 Gansevoort St Fl 9
Website: http://www.avenuetx.com/
CEO: N/A
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.59
Change:
$0.00
(
1.64%)
Days Range: $0.57 - $0.59
Beta: 0.71
52wk. High: $2.92
52wk. Low: $0.53
Ytd. Change -46.66%
50 Day Moving Average: $0.68
200 Day Moving Average: $0.97
Shares Outstanding: 8964222
Valuation
Market Cap: 537.6M
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A